JPWO2019222188A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019222188A5 JPWO2019222188A5 JP2020564674A JP2020564674A JPWO2019222188A5 JP WO2019222188 A5 JPWO2019222188 A5 JP WO2019222188A5 JP 2020564674 A JP2020564674 A JP 2020564674A JP 2020564674 A JP2020564674 A JP 2020564674A JP WO2019222188 A5 JPWO2019222188 A5 JP WO2019222188A5
- Authority
- JP
- Japan
- Prior art keywords
- icos
- cells
- agonist
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000556 agonist Substances 0.000 claims 28
- 102100013077 CD4 Human genes 0.000 claims 21
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 20
- 108090001123 antibodies Proteins 0.000 claims 16
- 102000004965 antibodies Human genes 0.000 claims 16
- 239000000725 suspension Substances 0.000 claims 15
- 238000009534 blood test Methods 0.000 claims 14
- 210000004027 cells Anatomy 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 239000011886 peripheral blood Substances 0.000 claims 13
- 238000002560 therapeutic procedure Methods 0.000 claims 13
- 230000001093 anti-cancer Effects 0.000 claims 12
- 102100017504 TBX21 Human genes 0.000 claims 11
- 101700014592 TBX21 Proteins 0.000 claims 11
- 230000003042 antagnostic Effects 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100019461 CD28 Human genes 0.000 claims 1
- 101700033362 CD28 Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 108090000393 Muromonab-CD3 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 239000006143 cell culture media Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000003834 intracellular Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000000737 periodic Effects 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 230000003442 weekly Effects 0.000 claims 1
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862671181P | 2018-05-14 | 2018-05-14 | |
US62/671,181 | 2018-05-14 | ||
US201862679346P | 2018-06-01 | 2018-06-01 | |
US62/679,346 | 2018-06-01 | ||
US201862750026P | 2018-10-24 | 2018-10-24 | |
US62/750,026 | 2018-10-24 | ||
US201962827312P | 2019-04-01 | 2019-04-01 | |
US62/827,312 | 2019-04-01 | ||
PCT/US2019/032184 WO2019222188A1 (en) | 2018-05-14 | 2019-05-14 | Methods of treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021523213A JP2021523213A (ja) | 2021-09-02 |
JPWO2019222188A5 true JPWO2019222188A5 (ru) | 2022-05-20 |
Family
ID=66690990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564674A Pending JP2021523213A (ja) | 2018-05-14 | 2019-05-14 | 癌を治療する方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US11292840B2 (ru) |
EP (1) | EP3793598A1 (ru) |
JP (1) | JP2021523213A (ru) |
CN (1) | CN112703012A (ru) |
WO (1) | WO2019222188A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10980804B2 (en) | 2013-01-18 | 2021-04-20 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
US20200024351A1 (en) * | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
EP3870610A1 (en) * | 2018-10-24 | 2021-09-01 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
US20230089426A1 (en) * | 2020-01-13 | 2023-03-23 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
EP4139358A1 (en) * | 2020-04-20 | 2023-03-01 | Jounce Therapeutics, Inc. | Compositions and methods for vaccination and the treatment of infectious diseases |
GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
CN112807425A (zh) * | 2021-01-14 | 2021-05-18 | 南方医科大学深圳医院 | 一种tTIM融合蛋白疫苗、制备方法及应用 |
CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO2012131004A2 (en) | 2011-03-31 | 2012-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
ES2733546T3 (es) | 2013-03-15 | 2019-11-29 | Bristol Myers Squibb Co | Inhibidores de IDO |
CN107530428B (zh) | 2015-03-23 | 2022-05-13 | 震动疗法股份有限公司 | Icos的抗体 |
AU2016342269A1 (en) | 2015-10-22 | 2018-03-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
WO2018029474A2 (en) * | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
CN116640214A (zh) | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
-
2019
- 2019-05-14 EP EP19728206.4A patent/EP3793598A1/en not_active Withdrawn
- 2019-05-14 JP JP2020564674A patent/JP2021523213A/ja active Pending
- 2019-05-14 CN CN201980047070.3A patent/CN112703012A/zh active Pending
- 2019-05-14 WO PCT/US2019/032184 patent/WO2019222188A1/en unknown
- 2019-05-14 US US16/411,744 patent/US11292840B2/en active Active
-
2022
- 2022-03-31 US US17/709,712 patent/US20220332823A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ishikawa et al. | Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer | |
RU2017137020A (ru) | Антитела к icos | |
Seystahl et al. | Therapeutic options in recurrent glioblastoma—An update | |
JP5642328B2 (ja) | Nk細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物 | |
AU2017249698B2 (en) | Ex vivo bite-activated T cells | |
Ohata et al. | Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen | |
Piotrowicz et al. | A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells | |
WO2018102785A2 (en) | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors | |
JPWO2019222188A5 (ru) | ||
Magalhaes et al. | CD19 chimeric antigen receptor T cells from patients with chronic lymphocytic leukemia display an elevated IFN-γ production profile | |
WO2017205213A1 (en) | Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer | |
CN114222758A (zh) | 抗bcma抗体及其在car-t领域中的应用 | |
Jiang et al. | Addressing patient to patient variability for autologous CAR T therapies | |
CN110520539A (zh) | 预测抗癌药的临床结果的方法 | |
Nakase et al. | Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies | |
Maharaj et al. | Differential regulation of human T-cells by TGR-1202, a novel PI3Kδ inhibitor | |
EP4058805B1 (en) | Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment | |
CN113073079A (zh) | 增强活性的nk免疫细胞在制备治疗癌症的药物中的用途 | |
Madi et al. | CD8 agonism functionally activates memory T cells and enhances antitumor immunity | |
Ma et al. | Automatic generation of lymphocyte heterogeneity: Division‐dependent changes in the expression of CD27, CCR7 and CD45 by activated human naive CD4+ T cells are independently regulated | |
Wang et al. | SIRP-alpha-IL-6 axis induces immunosuppressive macrophages in non-small-cell lung cancer | |
US20240053360A1 (en) | Methods of selectively targeting cd6 high cells and decreasing activity of teff cells | |
Sato et al. | Adoptive γδT-cell transfer alone or combined with chemotherapy for the treatment of advanced esophageal cancer | |
Novitzky et al. | Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag) | |
US20240158869A1 (en) | Factors for optimizing immunotherapy |